VALMONT INDUSTRIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VALMONT INDUSTRIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 29, 2012 | $3.17B | Feb 26, 2013 |
| FY2011 | Dec 31, 2011 | $2.77B | Feb 28, 2012 |
| FY2011 | Dec 25, 2010 | $2.03B | Feb 28, 2012 |
| FY2011 | Dec 26, 2009 | $1.84B | Feb 28, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $4.10B | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $4.08B | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | $4.17B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $4.35B | Feb 25, 2025 |
| FY2022 | Dec 24, 2022 | $4.35B | Mar 1, 2023 |
| FY2023 | Dec 25, 2021 | $3.50B | Feb 28, 2024 |
| FY2019 | Dec 26, 2020 | $798.38M | Feb 24, 2021 |
| FY2019 | Sep 26, 2020 | $733.97M | Feb 24, 2021 |
| FY2019 | Jun 27, 2020 | $688.81M | Feb 24, 2021 |
| FY2019 | Mar 28, 2020 | $674.20M | Feb 24, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $714.98M | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $680.78M | Feb 28, 2018 |
| FY2017 | Jul 1, 2017 | $712.74M | Feb 28, 2018 |
| FY2017 | Apr 1, 2017 | $637.47M | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $674.58M | Feb 28, 2018 |
| FY2017 | Sep 24, 2016 | $610.25M | Feb 28, 2018 |
| FY2017 | Jun 25, 2016 | $640.25M | Feb 28, 2018 |
| FY2017 | Mar 26, 2016 | $596.61M | Feb 28, 2018 |
| FY2016 | Dec 26, 2015 | $633.83M | Mar 1, 2017 |
| FY2016 | Sep 26, 2015 | $632.58M | Mar 1, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $1.24B | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $1.24B | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | $1.24B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.13B | Feb 25, 2025 |
| FY2023 | Dec 25, 2021 | $883.89M | Feb 28, 2024 |
| FY2019 | Dec 26, 2020 | $204.58M | Feb 24, 2021 |
| FY2019 | Sep 26, 2020 | $190.75M | Feb 24, 2021 |
| FY2019 | Jun 27, 2020 | $183.94M | Feb 24, 2021 |
| FY2019 | Mar 28, 2020 | $186.25M | Feb 24, 2021 |
| FY2019 | Dec 28, 2019 | $166.59M | Feb 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $350.27M | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $348.26M | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | $150.85M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $250.86M | Feb 25, 2025 |
| FY2023 | Dec 25, 2021 | $195.63M | Feb 28, 2024 |
| FY2010 | Dec 25, 2010 | $94.38M | Feb 23, 2011 |
| FY2010 | Dec 26, 2009 | $150.56M | Feb 23, 2011 |
| FY2010 | Dec 27, 2008 | $132.40M | Feb 23, 2011 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $415.58M | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $524.58M | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | $291.56M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $433.25M | Feb 25, 2025 |
| FY2022 | Dec 24, 2022 | $433.25M | Mar 1, 2023 |
| FY2023 | Dec 25, 2021 | $286.79M | Feb 28, 2024 |
| FY2022 | Dec 26, 2020 | $225.95M | Mar 1, 2023 |
| FY2019 | Dec 28, 2019 | $227.91M | Feb 23, 2022 |
| FY2019 | Dec 29, 2018 | $212.17M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $267.08M | Feb 26, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $33.00M | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $59.00M | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | $55.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $46.00M | Feb 25, 2025 |
| FY2023 | Dec 25, 2021 | $37.00M | Feb 28, 2024 |
| FY2022 | Dec 26, 2020 | $21.40M | Mar 1, 2023 |
| FY2019 | Dec 28, 2019 | $13.90M | Feb 23, 2022 |
| FY2019 | Dec 29, 2018 | $11.50M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $11.60M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $8.30M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $717.63M | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $716.63M | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | $768.42M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $692.98M | Feb 25, 2025 |
| FY2023 | Dec 25, 2021 | $590.61M | Feb 28, 2024 |
| FY2022 | Dec 26, 2020 | $522.92M | Mar 1, 2023 |
| FY2019 | Dec 28, 2019 | $454.78M | Feb 23, 2022 |
| FY2019 | Dec 29, 2018 | $440.22M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $414.69M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $410.87M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $456.48M | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $572.68M | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | $306.78M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $326.27M | Feb 25, 2025 |
| FY2023 | Dec 25, 2021 | $65.94M | Feb 28, 2024 |
| FY2022 | Dec 26, 2020 | $316.29M | Mar 1, 2023 |
| FY2019 | Dec 28, 2019 | $307.61M | Feb 23, 2022 |
| FY2019 | Dec 29, 2018 | $153.01M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $133.15M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $232.82M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $145.04M | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $79.45M | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | $96.77M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $93.29M | Feb 25, 2025 |
| FY2023 | Dec 25, 2021 | $107.79M | Feb 28, 2024 |
| FY2022 | Dec 26, 2020 | $106.70M | Mar 1, 2023 |
| FY2019 | Dec 28, 2019 | $97.43M | Feb 23, 2022 |
| FY2019 | Dec 29, 2018 | $71.99M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $55.27M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $57.92M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $3.37B | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $3.33B | Feb 24, 2026 |
| FY2024 | Dec 30, 2023 | $3.48B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $3.56B | Feb 28, 2024 |
| FY2023 | Dec 25, 2021 | $3.45B | Feb 28, 2024 |
| FY2022 | Dec 26, 2020 | $2.95B | Mar 1, 2023 |
| FY2019 | Dec 28, 2019 | $2.81B | Feb 23, 2022 |
| FY2019 | Dec 29, 2018 | $2.58B | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $2.60B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $2.39B | Feb 27, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $1.73B | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $1.74B | Feb 24, 2026 |
| FY2024 | Dec 30, 2023 | $2.06B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.92B | Feb 28, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $1.63B | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $1.54B | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | $1.35B | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $1.58B | Feb 24, 2026 |
| FY2024 | Dec 25, 2021 | $1.39B | Feb 25, 2025 |
| FY2023 | Dec 26, 2020 | $1.18B | Feb 28, 2024 |
| FY2019 | Dec 28, 2019 | $1.14B | Feb 24, 2021 |
| FY2019 | Dec 29, 2018 | $1.06B | Feb 26, 2020 |
| FY2018 | Dec 30, 2017 | $1.11B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $943.48M | Feb 28, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $570.95M | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $623.85M | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | $632.96M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $739.86M | Feb 25, 2025 |
| FY2023 | Dec 25, 2021 | $708.57M | Feb 28, 2024 |
| FY2022 | Dec 26, 2020 | $430.32M | Mar 1, 2023 |
| FY2019 | Dec 28, 2019 | $428.86M | Feb 23, 2022 |
| FY2019 | Dec 29, 2018 | $385.21M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $337.72M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $321.11M | Feb 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $3.16B | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $2.94B | Feb 24, 2026 |
| FY2024 | Dec 30, 2023 | $2.64B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $2.59B | Feb 28, 2024 |
| FY2022 | Dec 25, 2021 | $2.39B | Mar 1, 2023 |
| FY2019 | Dec 26, 2020 | $2.25B | Feb 23, 2022 |
| FY2019 | Dec 28, 2019 | $2.17B | Feb 24, 2021 |
| FY2019 | Dec 29, 2018 | $2.03B | Feb 26, 2020 |
| FY2018 | Dec 30, 2017 | $1.95B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $1.87B | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $187.14M | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $164.32M | Feb 24, 2026 |
| FY2024 | Dec 30, 2023 | $203.04M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $185.41M | Feb 28, 2024 |
| FY2022 | Dec 25, 2021 | $177.23M | Mar 1, 2023 |
| FY2019 | Dec 26, 2020 | $400.73M | Feb 23, 2022 |
| FY2019 | Dec 28, 2019 | $353.54M | Feb 24, 2021 |
| FY2019 | Dec 29, 2018 | $313.21M | Feb 26, 2020 |
| FY2017 | Dec 30, 2017 | $492.81M | Feb 28, 2018 |
| FY2018 | Dec 31, 2016 | $399.95M | Feb 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $795.66M | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $730.63M | Feb 24, 2026 |
| FY2024 | Dec 30, 2023 | $1.11B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $872.13M | Feb 28, 2024 |
| FY2022 | Dec 25, 2021 | $951.96M | Mar 1, 2023 |
| FY2019 | Dec 26, 2020 | $731.18M | Feb 23, 2022 |
| FY2019 | Dec 28, 2019 | $765.70M | Feb 24, 2021 |
| FY2019 | Dec 29, 2018 | $742.60M | Feb 26, 2020 |
| FY2018 | Dec 30, 2017 | $754.85M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $755.65M | Feb 28, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 16 | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | 17 | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | 6 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 11 | Feb 25, 2025 |
| FY2023 | Dec 25, 2021 | 9 | Feb 28, 2024 |
| FY2019 | Dec 26, 2020 | 1 | Feb 24, 2021 |
| FY2019 | Sep 26, 2020 | 1 | Feb 24, 2021 |
| FY2019 | Jun 27, 2020 | 1 | Feb 24, 2021 |
| FY2019 | Mar 28, 2020 | 2 | Feb 24, 2021 |
| FY2019 | Dec 28, 2019 | 1 | Feb 24, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 16 | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | 17 | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | 6 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 11 | Feb 25, 2025 |
| FY2023 | Dec 25, 2021 | 9 | Feb 28, 2024 |
| FY2019 | Dec 26, 2020 | 1 | Feb 24, 2021 |
| FY2019 | Sep 26, 2020 | 1 | Feb 24, 2021 |
| FY2019 | Jun 27, 2020 | 1 | Feb 24, 2021 |
| FY2019 | Mar 28, 2020 | 1 | Feb 24, 2021 |
| FY2019 | Dec 28, 2019 | 1 | Feb 24, 2021 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $52.48M | Feb 24, 2026 |
| FY2025 | Dec 28, 2024 | $48.36M | Feb 24, 2026 |
| FY2025 | Dec 30, 2023 | $49.52M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $45.81M | Feb 25, 2025 |
| FY2023 | Dec 25, 2021 | $41.41M | Feb 28, 2024 |
| FY2022 | Dec 26, 2020 | $36.93M | Mar 1, 2023 |
| FY2019 | Dec 28, 2019 | $32.64M | Feb 23, 2022 |
| FY2019 | Dec 29, 2018 | $33.73M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $33.86M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $34.05M | Feb 27, 2019 |